Compare Novartis AG (NVS) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Rent the Runway Inc — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Rent the Runway Inc trades at $1.81 (market cap $61.75M). The key difference: Novartis AG is far larger — about 4349.3× Rent the Runway Inc's market cap, and Novartis AG pays a 3.31% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Rent the Runway Inc for 56 Days on average.
| NVS | RENT | |
|---|---|---|
Market Cap | $268.57B | $61.75M |
Volume | 1,532,573 | 193,323 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $9.39 |
52-Week Low | $121.80 | $1.55 |
Typical Hold Time | 82 Days | 56 Days |
Enterprise Value | $309.89B | $228.75M |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
RENT trades at $1.68, up 1.82% today, amid a bearish technical signal and mixed fundamentals. The company reported Q2 2026 revenue growth of 20.8% YoY to $97.7M, with improved gross margins, but faces negative shareholder equity of -$182.5M and a high debt-to-asset ratio of 139.62. Recent CEO appointment and multiple law firm investigations create contrasting sentiment.
Outlook remains cautious due to persistent net losses, high leverage, and legal scrutiny, though revenue growth and margin expansion offer potential upside. Risks include execution challenges and debt burden, while analyst consensus leans Hold (57.89%) with no Sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
